Best Classification

Re-classification of more than 50% of the intermediate risk group and full identification of the favorable group with one test.

One Test Identifies the Favorable Group and Minimizes Intermediate Risk Group

Using traditional cytogenetic methods, over 60% of the AML patients are assigned to the intermediate group. Using the AMLprofiler, more than 50% of this intermediate group is reclassified into either the favorable or the unfavorable group, significantly increasing treatment efficacy.

Whereas other protocols require multiple tests for the identification of the favorable group, the AMLprofiler provides you this classification in one test, and better.

Nine assays in one

Three days to diagnosis

Validated test

Clear report